PIAS1 blocking peptide

PIAS1 Antibody (C-term) Blocking Peptide

• Gene Names: PIAS1; GBP; ZMIZ3; DDXBP1; GU/RH-II
• Synonyms: PIAS1; PIAS1 Antibody (C-term) Blocking Peptide; E3 SUMO-protein ligase PIAS1; 632-; DEAD/H box-binding protein 1; Gu-binding protein; GBP; Protein inhibitor of activated STAT protein 1; RNA helicase II-binding protein; DDXBP1; PIAS1 blocking peptide

• Specificity: The synthetic peptide sequence used to generate the antibody was selected from the C-term region of human PIAS1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
• Form/Format: The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
• Sequence Length: 651

• Cellular Location: Nucleus speckle. Nucleus, PML body Note: Interaction with CSRP2 may induce a partial redistribution along the cytoskeleton
• Tissue Location: Expressed in numerous tissues with highest level in testis.
• Preparation and Storage: Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C.

Related Product Information for PIAS1 blocking peptide

Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Sumoylates PML (at'Lys-65' and 'Lys-160') and PML-RAR and promotes their ubiquitin-mediated degradation. PIAS1-mediated sumoylation of PML promotes its interaction with CSNK2A1/CK2 which in turn promotes PML phosphorylation and degradation (By similarity). Enhances the sumoylation of MTA1 and may participate in its paralog-selective sumoylation.

NCBI and Uniprot Product Information

• NCBI GI #: 20138891
• NCBI GeneID: 8554
• UniProt Accession #: O75925; Q147X4; Q99751; Q9UN02; B2RB67; B3KSY9; C5J4B4
• Molecular Weight: 36,204 Da
• NCBI Official Full Name: E3 SUMO-protein ligase PIAS1
• NCBI Official Synonym Full Names: protein inhibitor of activated STAT 1
• NCBI Official Symbol: PIAS1
• NCBI Official Synonym Symbols: GBP; ZMIZ3; DDXBP1; GU/RH-II
• NCBI Protein Information: E3 SUMO-protein ligase PIAS1
• UniProt Protein Name: E3 SUMO-protein ligase PIAS1
• Protein Family: E3 SUMO-protein ligase
• UniProt Gene Name: PIAS1
• UniProt Synonym Gene Names: DDXBP1; GBP
• UniProt Entry Name: PIAS1_HUMAN

NCBI Description

This gene encodes a member of the protein inhibitor of activated STAT (PIAS) family. PIAS proteins function as SUMO E3 ligases and play important roles in many cellular processes by mediating the sumoylation of target proteins. This protein plays a central role as a transcriptional coregulator of numerous cellular pathways includign the STAT1 and nuclear factor kappaB pathways. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016]

Uniprot Description

PIAS1: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. Plays a crucial role as a transcriptional coregulation in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. In vitro, binds A/T-rich DNA. The effects of this transcriptional coregulation, transactivation or silencing, may vary depending upon the biological context. Together with PRMT1, may repress STAT1 transcriptional activity, in the late phase of interferon gamma (IFN-gamma) signaling. Interacts with NCOA2 and AR. Interacts with NR2C1; the interaction promotes its sumoylation. Interacts with DDX21, CSRP2, AXIN1, JUN, UBE2I, SUMO1, SATB2, PLAG1, TP53 and STAT1 (dimer), following IFNA1-stimulation. Interacts with SP3 (preferentially when SUMO-modified). Interacts with KLF8; the interaction results in SUMO ligation and repression of KLF8 transcriptional activity and of its cell cycle progression into G(1) phase. Interacts with STAT1. Interacts with CHUK/IKKA; this interaction induces PIAS1 phosphorylation. Interacts with PTK2/FAK1; the interaction promotes its sumoylation. Interacts with DDX5. Expressed in numerous tissues with highest level in testis. Belongs to the PIAS family.

Protein type: SUMO conjugating system; Transcription, coactivator/corepressor; EC 6.3.2.-; Nuclear receptor co-regulator

Chromosomal Location of Human Ortholog: 15q

Cellular Component: nucleoplasm; nucleus; PML body

Molecular Function: enzyme binding; protein binding; SUMO ligase activity; transcription corepressor activity

Biological Process: JAK-STAT cascade; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; positive regulation of protein sumoylation; protein sumoylation; regulation of cell proliferation